These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 3712868)
1. Cardiovascular effects of NPK-1886, a new dihydropyridine compound with calcium entry blocking activity. Nagura J; Murayama B; Harada N; Suzuki K; Miyano T; Yajima M; Takeya K Jpn J Pharmacol; 1986 Mar; 40(3):399-409. PubMed ID: 3712868 [TBL] [Abstract][Full Text] [Related]
2. Antihypertensive and cardiovascular effects of the new dihydropyridine derivative methyl (E)-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl- 4-(3-nitrophenyl)pyridine-3,5-dicarboxylate. Yamaura T; Kase N; Kita H; Uematsu T Arzneimittelforschung; 1986; 36(1):29-34. PubMed ID: 3754142 [TBL] [Abstract][Full Text] [Related]
3. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors. Burges RA; Gardiner DG; Gwilt M; Higgins AJ; Blackburn KJ; Campbell SF; Cross PE; Stubbs JK J Cardiovasc Pharmacol; 1987 Jan; 9(1):110-9. PubMed ID: 2434785 [TBL] [Abstract][Full Text] [Related]
4. Antihypertensive activity of OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist, in rats. Nakayama N; Ikezono K; Mori T; Yamashita S; Nakayama S; Tanaka Y; Hosokawa T; Minami Y; Masutani K; Yamamura Y J Cardiovasc Pharmacol; 1990 May; 15(5):836-44. PubMed ID: 1692946 [TBL] [Abstract][Full Text] [Related]
5. Effects of nilvadipine on the cardiovascular system in experimental animals. Ohtsuka M; Koibuchi Y; Sakai S; Tsujioka K; Fujiwara T; Ozaki T; Maeda K; Motoyama I; Horiai H; Ono T Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444 [TBL] [Abstract][Full Text] [Related]
6. Cardiac versus vascular effects of a new dihydropyridine derivative, CV-4093. In vitro comparison with other calcium antagonists. Nakaya H; Hattori Y; Nakao Y; Kanno M Eur J Pharmacol; 1988 Jan; 146(1):35-43. PubMed ID: 3350058 [TBL] [Abstract][Full Text] [Related]
7. [Vasodilator effects of LF 2.0254, a new 1,4-dihydropyridine. Comparison with nifedipine]. Pruneau D; Roy F; Brown NL Therapie; 1989; 44(3):203-8. PubMed ID: 2781506 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular pharmacology of nicardipine in animals. Takenaka T; Asano M; Shiono K; Shibasaki M; Inagaki O Br J Clin Pharmacol; 1985; 20 Suppl 1(Suppl 1):7S-22S. PubMed ID: 4027153 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular activities of the new potent and long-lasting antihypertensive calcium entry blocker (+-)-3-ethyl,5-methyl,2- ([2-(formylamino)-ethyl]- thiomethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicar box ylate. Germini M; Passoni A; Casciarri I; Bosetti P; Piazzoni L; Cazzulani P; Gandolfi CA; Tofanetti O; Ceserani R Arzneimittelforschung; 1992 Jan; 42(1):1-8. PubMed ID: 1586373 [TBL] [Abstract][Full Text] [Related]
11. In vitro assessment for vascular selectivity of a new dihydropyridine derivative, NB-818. Hattori Y; Fukao M; Houzen H; Qi F; Yamada Y; Kanno M Eur J Pharmacol; 1996 Apr; 301(1-3):99-106. PubMed ID: 8773452 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Shibata S; Satake N; Kodama I; Hester RK; Wang CG; Jino H; Hojo M; Tatsumi H; Gandhi V; Jones DJ Eur J Pharmacol; 1991 Oct; 203(3):337-44. PubMed ID: 1773820 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular properties of LF 2.0254, a new potent vasoselective calcium channel blocker with a slow onset of action. Pruneau D; Roy F; Brown NL Fundam Clin Pharmacol; 1990; 4(2):223-43. PubMed ID: 2112508 [TBL] [Abstract][Full Text] [Related]
15. Amlodipine, a new 1,4-dihydropyridine calcium antagonist with a particularly strong antihypertensive profile. Fleckenstein A; Frey M; Zorn J; Fleckenstein-Grün G Am J Cardiol; 1989 Nov; 64(17):21I-34I. PubMed ID: 2530884 [TBL] [Abstract][Full Text] [Related]
16. Vascular versus myocardial selectivity of dihydropyridine calcium antagonists as studied in vivo and in vitro. Nordlander M; Abrahamsson T; Akerblom B; Thalén P Pharmacol Toxicol; 1995 Jan; 76(1):56-62. PubMed ID: 7753759 [TBL] [Abstract][Full Text] [Related]
17. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding. Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181 [TBL] [Abstract][Full Text] [Related]
18. [Comparison of actions of m-nifedipine and nifedipine on isolated guinea pig atria and rabbit aortic strips]. Wu XD; Rao MR Zhongguo Yao Li Xue Bao; 1989 Jan; 10(1):58-61. PubMed ID: 2816403 [TBL] [Abstract][Full Text] [Related]
19. MDL 72567, a dihydropyridine calcium-antagonist, that causes vasodilation and direct sinus bradycardia. Spedding M; DiFrancesco GF; Mir AK; Petty MA; Berg C; Gittos M J Cardiovasc Pharmacol; 1987 Jul; 10(1):62-71. PubMed ID: 2441155 [TBL] [Abstract][Full Text] [Related]
20. Dissociation between calcium influx blockage and smooth muscle relaxation by nifedipine in spontaneously hypertensive rats. Rinaldi GJ; Amado Cattaneo E; Mattiazzi A; Cingolani HE Circ Res; 1987 Mar; 60(3):367-74. PubMed ID: 3581445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]